Cargando…

Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea

BACKGROUND: Although endocrine therapy is an effective treatment for breast cancer, its antiestrogen effects are associated with increased risks of cardiovascular diseases and type 2 diabetes. This study aimed to investigate the association between endocrine therapy and the risk of cardiovascular di...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ji‐Eun, Choi, Jaesung, Park, JooYong, Han, Wonshik, Kang, Daehee, Choi, Ji‐Yeob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673673/
https://www.ncbi.nlm.nih.gov/pubmed/36250658
http://dx.doi.org/10.1161/JAHA.122.026743
_version_ 1784832994708553728
author Kim, Ji‐Eun
Choi, Jaesung
Park, JooYong
Han, Wonshik
Kang, Daehee
Choi, Ji‐Yeob
author_facet Kim, Ji‐Eun
Choi, Jaesung
Park, JooYong
Han, Wonshik
Kang, Daehee
Choi, Ji‐Yeob
author_sort Kim, Ji‐Eun
collection PubMed
description BACKGROUND: Although endocrine therapy is an effective treatment for breast cancer, its antiestrogen effects are associated with increased risks of cardiovascular diseases and type 2 diabetes. This study aimed to investigate the association between endocrine therapy and the risk of cardiovascular diseases and type 2 diabetes among breast cancer survivors in Korea, in consideration of various age groups. METHODS AND RESULTS: In the National Health Insurance Service database of Korea, a total of 133 171 patients with breast cancer aged ≥20 years were included in the current study. Endocrine therapy was treated as time‐varying exposure, and patients were categorized as nonusers, selective estrogen receptor modulator users, aromatase inhibitor users, and both users. Time‐dependent Cox regression models were used to estimate hazard ratios (HRs) and 95% CIs. Age at diagnosis, socioeconomic status, histological type, other treatments, and comorbidities were adjusted in the model. Compared with nonusers, selective estrogen receptor modulator users were associated with higher risks of stroke (HR, 1.20 [95% CI, 1.04–1.40]) and venous thromboembolism (HR, 1.47 [95% CI, 1.13–1.90]), whereas aromatase inhibitor users were associated with a higher risk of coronary heart disease (HR, 1.22 [95% CI, 1.06–1.41]). The risk of type 2 diabetes was associated with selective estrogen receptor modulator users (HR, 1.13 [95% CI, 1.05–1.21]), aromatase inhibitor users (HR, 1.14 [95% CI, 1.05–1.23]), and both users (HR, 1.24 [95% CI, 1.10–1.39]). In particular, the risk of a composite of cardiovascular diseases was higher in younger or premenopausal patients. CONCLUSIONS: In breast cancer survivors in Korea, endocrine therapy is associated with a higher risk of cardiovascular diseases and type 2 diabetes. Monitoring of cancer comorbidities after endocrine therapy is needed in younger and older patients.
format Online
Article
Text
id pubmed-9673673
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-96736732022-11-21 Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea Kim, Ji‐Eun Choi, Jaesung Park, JooYong Han, Wonshik Kang, Daehee Choi, Ji‐Yeob J Am Heart Assoc Original Research BACKGROUND: Although endocrine therapy is an effective treatment for breast cancer, its antiestrogen effects are associated with increased risks of cardiovascular diseases and type 2 diabetes. This study aimed to investigate the association between endocrine therapy and the risk of cardiovascular diseases and type 2 diabetes among breast cancer survivors in Korea, in consideration of various age groups. METHODS AND RESULTS: In the National Health Insurance Service database of Korea, a total of 133 171 patients with breast cancer aged ≥20 years were included in the current study. Endocrine therapy was treated as time‐varying exposure, and patients were categorized as nonusers, selective estrogen receptor modulator users, aromatase inhibitor users, and both users. Time‐dependent Cox regression models were used to estimate hazard ratios (HRs) and 95% CIs. Age at diagnosis, socioeconomic status, histological type, other treatments, and comorbidities were adjusted in the model. Compared with nonusers, selective estrogen receptor modulator users were associated with higher risks of stroke (HR, 1.20 [95% CI, 1.04–1.40]) and venous thromboembolism (HR, 1.47 [95% CI, 1.13–1.90]), whereas aromatase inhibitor users were associated with a higher risk of coronary heart disease (HR, 1.22 [95% CI, 1.06–1.41]). The risk of type 2 diabetes was associated with selective estrogen receptor modulator users (HR, 1.13 [95% CI, 1.05–1.21]), aromatase inhibitor users (HR, 1.14 [95% CI, 1.05–1.23]), and both users (HR, 1.24 [95% CI, 1.10–1.39]). In particular, the risk of a composite of cardiovascular diseases was higher in younger or premenopausal patients. CONCLUSIONS: In breast cancer survivors in Korea, endocrine therapy is associated with a higher risk of cardiovascular diseases and type 2 diabetes. Monitoring of cancer comorbidities after endocrine therapy is needed in younger and older patients. John Wiley and Sons Inc. 2022-10-17 /pmc/articles/PMC9673673/ /pubmed/36250658 http://dx.doi.org/10.1161/JAHA.122.026743 Text en © 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Kim, Ji‐Eun
Choi, Jaesung
Park, JooYong
Han, Wonshik
Kang, Daehee
Choi, Ji‐Yeob
Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea
title Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea
title_full Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea
title_fullStr Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea
title_full_unstemmed Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea
title_short Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea
title_sort effects of endocrine therapy on cardiovascular diseases and type 2 diabetes among breast cancer survivors: the national health insurance service database of korea
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673673/
https://www.ncbi.nlm.nih.gov/pubmed/36250658
http://dx.doi.org/10.1161/JAHA.122.026743
work_keys_str_mv AT kimjieun effectsofendocrinetherapyoncardiovasculardiseasesandtype2diabetesamongbreastcancersurvivorsthenationalhealthinsuranceservicedatabaseofkorea
AT choijaesung effectsofendocrinetherapyoncardiovasculardiseasesandtype2diabetesamongbreastcancersurvivorsthenationalhealthinsuranceservicedatabaseofkorea
AT parkjooyong effectsofendocrinetherapyoncardiovasculardiseasesandtype2diabetesamongbreastcancersurvivorsthenationalhealthinsuranceservicedatabaseofkorea
AT hanwonshik effectsofendocrinetherapyoncardiovasculardiseasesandtype2diabetesamongbreastcancersurvivorsthenationalhealthinsuranceservicedatabaseofkorea
AT kangdaehee effectsofendocrinetherapyoncardiovasculardiseasesandtype2diabetesamongbreastcancersurvivorsthenationalhealthinsuranceservicedatabaseofkorea
AT choijiyeob effectsofendocrinetherapyoncardiovasculardiseasesandtype2diabetesamongbreastcancersurvivorsthenationalhealthinsuranceservicedatabaseofkorea